Efficacy and safety of intravascular lithotripsy in percutaneous coronary intervention in patients with non-ST elevation acute coronary syndrome with calcified lesions
Efficacy and safety of intravascular lithotripsy in percutaneous coronary intervention in patients with non-ST elevation acute coronary syndrome with calcified lesions
Objective To observe the clinical efficacy of intravascular lithotripsy(intravascular lithotripsy,IVL)in percutaneous coronary intervention(percutaneous coronary intervention,PCI)in patients with non-ST elevation acute coronary syndrome with calcified lesions.Methods All the patients treated with IVL in the Department of Jiaozuo People's Hospital and Jiaozuo Central Hospital of Coal Industry Group from October 2022 to April 2023.Patient demographic characteristics,clinical data,specific procedure data and related complications were collected to appraise the efficacy and safety of IVL.Results Forty-three patients received PCI with adjuvant IVL during this period,and the mean age was(67.77±7.21).The proportion of the patients with unstable angina was 76.7%and 23.3%with NSTEMI.60.5%was in situ lesion,25.6%was in-stent restenosis,and 13.9%was"salvage"treatment with incomplete stent inflation.The surgical success rate was 100%.After stenting or DCB implantation,the restenosis rate was(3.372±4.040)%and the minimum lumen area was(9.416±0.940)mm2.One patient had slow flow during the perioperative period.The perioperative MACE incidence was 16.7%,all of which were surgery-related myocardial infarction,totaling 7 cases.Conclusions IVL is a safe and effective new method to modify coronary artery calcification to achieve adequate stent expansion.
维普
万方数据